Is pimetibi currently on the market in China?

Pimitespib is not currently on the market in China, and patients cannot purchase the drug through regular domestic channels. Since it has not yet been approved by the China Food and Drug Administration, pimetibib has not entered the market in China. If patients need to use the drug, they may need to rely on overseas channels to purchase it.

Currently, the original drug of pimetibi is only available in some international markets, especially in Japan. The Japanese version of the original drug Pimetibi is relatively expensive, with a box costing about more than 10,000 yuan, which may be a considerable expense for some patients. Although the therapeutic effect of pimetibib has shown good efficacy in clinical trials, the high price is still a major problem faced by patients.

Since pimistebi has not yet been launched in China, and there are currently no generic versions of pimistebi, patients' choices are limited. For patients in need, they can be purchased through cross-border e-commerce, overseas pharmacies or related channels. However, this method of purchasing involves certain legal and safety risks. Patients should be careful when choosing to ensure the legality of the purchasing channel and the quality of the medicine.

With the accumulation of international clinical data and the gradual promotion of pimetibi around the world, the drug is likely to be approved by more countries and regions in the future and enter more markets. It is hoped that as time goes by, pimetibib will be approved by the China Food and Drug Administration so that more patients can benefit from it. Until then, patients need to follow their doctor's advice and weigh the benefits and risks of the drug.

Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/